Intracellular signaling by cathepsin X: Molecular mechanisms and diagnostic and therapeutic opportunities in cancer

Seminars in Cancer Biology

Volumn 31, Issue , 2015, Pages 76-83

  Kos, Janko ^a,b   Vižin, Tjaša ^a   Fonović, Urša Pečar ^a   Pišlar, Anja ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

Adhesion; Cancer; Cathepsin X; Migration; Signaling

Indexed keywords

CATHEPSIN; CATHEPSIN X; CYSTEINE CATHEPSIN; HUNTINGTIN; INTEGRIN RECEPTOR; NEURON SPECIFIC ENOLASE; PROFILIN; PROFILIN 1; UNCLASSIFIED DRUG; BETA INTEGRIN; CATHEPSIN K;

BODY FLUID; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MODEL; CANCER PROGNOSIS; CELL ADHESION; CELL AGING; CELL MIGRATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TREATMENT RESPONSE; TUMOR PROMOTION; BIOLOGICAL MODEL; ENDOTHELIUM CELL; ENZYMOLOGY; INTRACELLULAR SPACE; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION;

CATHEPSIN K; CELL ADHESION; ENDOTHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INTEGRIN BETA CHAINS; INTRACELLULAR SPACE; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84923226334     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.05.001     Document Type: Review

References (87)

1. Rawlings N.D., Barrett A.J., Bateman A. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 2012, 40:D343-D350.
2. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006, 5:785-799.
3. Puente X.S., Sanchez L.M., Overall C.M., Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 2003, 4:544-558.
4. Kos J., Lah T.T. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer. Oncol Rep 1998, 5:1349-1361. [Review].
5. Schmitt M., Jaenicke F., Graeff H. Protease, matrix degradation and tumour-cell spread. Fybrinolysis 1992, 6:1-17.
6. Koblinski J.E., Ahram M., Sloane B.F. Unraveling the role of proteases in cancer. Clin Chim Acta 2000, 291:113-135.
7. Kostoulas G., Lang A., Nagase H., Baici A. Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Lett 1999, 455:286-290.
8. Lenarcic B., Kos J., Dolenc I., Lucovnik P., Krizaj I., Turk V. Cathepsin D inactivates cysteine proteinase inhibitors, cystatins. Biochem Biophys Res Commun 1988, 154:765-772.
9. Vasiljeva O., Turk B. Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumour invasion. Biochimie 2008, 90:380-386.
10. Obermajer N., Doljak B., Kos J. Cysteine cathepsins: regulators of antitumour immune response. Expert Opin Biol Ther 2006, 6:1295-1309.
11. Wang J., Chen L.L., Li Y., Guan X.Y. Overexpression of cathepsin Z contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. PLoS ONE 2011.
12. Turk V., Turk B., Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J 2001, 20:4629-4633.
13. Turk D., Guncar G. Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr D Biol Crystallogr 2003, 59:203-213.
14. Puzer L., Cotrin S.S., Cezari M.H., Hirata I.Y., Juliano M.A., Stefe I., et al. Recombinant human cathepsin X is a carboxymonopeptidase only: a comparison with cathepsins B and L. Biol Chem 2005, 386:1191-1195.
15. Guncar G., Podobnik M., Pungercar J., Strukelj B., Turk V., Turk D. Crystal structure of porcine cathepsin H determined at 2.1 A resolution: location of the mini-chain C-terminal carboxyl group defines cathepsin H aminopeptidase function. Structure 1998, 6:51-61.
16. Barrett A.J., Kirschke H. Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol 1981, 80:535-561.
17. Brix K., Dunkhorst A., Mayer K., Jordans S. Cysteine cathepsins: cellular roadmap to different functions. Biochimie 2008, 90:194-207.
18. Turk V., Kos J., Turk B. Cysteine cathepsins (proteases) - on the main stage of cancer. Cancer Cell 2004, 5:409-410.
19. Sivaraman J., Nagler D.K., Zhang R., Menard R., Cygler M. Crystal structure of human procathepsin X: a cysteine protease with the proregion covalently linked to the active site cysteine. J Mol Biol 2000, 295:939-951.
20. Kos J., Sekirnik A., Premzl A., Zavasnik Bergant V., Langerholc T., Turk B., et al. Carboxypeptidases cathepsins X and B display distinct protein profile in human cells and tissues. Exp Cell Res 2005, 306:103-113.
21. Pislar A., Kos J. Cysteine cathepsins in neurological disorders. Mol Neurobiol 2003, 49:1017-1030.
22. Kos J., Jevnikar Z., Obermajer N. The role of cathepsin X in cell signaling. Cell Adh Migr 2009, 3:164-166.
23. Nagler D.K., Kruger S., Kellner A., Ziomek E., Menard R., Buhtz P., et al. Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia. Prostate 2004, 60:109-119.
24. Rumpler G., Becker B., Hafner C., McClelland M., Stolz W., Landthaler M., et al. Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes. Exp Dermatol 2003, 12:761-771.
25. Krueger S., Kalinski T., Hundertmark T., Wex T., Kuster D., Peitz U., et al. Up-regulation of cathepsin X in Helicobacter pylori gastritis and gastric cancer. J Pathol 2005, 207:32-42.
26. Vizin T., Christensen I.J., Nielsen H.J., Kos J. Cathepsin X in serum from patients with colorectal cancer: relation to prognosis. Radiol Oncol 2012, 46:207-212.
27. Nagler D.K., Lechner A.M., Oettl A., Kozaczynska K., Scheuber H.P., Gippner-Steppert C., et al. An enzyme-linked immunosorbent assay for human cathepsin X, a potential new inflammatory marker. J Immunol Methods 2006, 308:241-250.
28. Wendt W., Zhu X-R., Lübbert H., Stichel C.C. Differential expression of cathepsin X in aging and pathological central nervous system of mice. Exp Neurol 2007, 204:525-540.
29. Obermajer N., Magister S., Kopitar A.N., Tepes B., Ihan A., Kos J. Cathepsin X prevents an effective immune response against Helicobacter pylori infection. Eur J Cell Biol 2009, 88:461-471.
30. Leichsenring A., Backer I., Wendt W., Andriske M., Schmitz B., Stichel C.C., et al. Differential expression of Cathepsin S and X in the spinal cord of a rat neuropathic pain model. BMC Neurosci 2008, 9:80.
31. Baker A.R., Zalwango S., Malone L.L., Igo R.P., Qiu F., Nsereko M., et al. Genetic susceptibility to tuberculosis associated with cathepsin Z haplotype in a Ugandan household contact study. Hum Immunol 2011, 72:426-430.
32. Obermajer N., Repnik U., Jevnikar Z., Turk B., Kreft M., Kos J. Cysteine protease cathepsin X modulates immune response via activation of beta2 integrins. Immunology 2008, 124:76-88.
33. Jevnikar Z., Obermajer N., Bogyo M., Kos J. The role of cathepsin X in the migration and invasiveness of T lymphocytes. J Cell Sci 2008, 121:2652-2661.
34. Obermajer N., Premzl A., Zavasnik Bergant T., Turk B., Kos J. Carboxypeptidase cathepsin X mediates beta2-integrin-dependent adhesion of differentiated U-937 cells. Exp Cell Res 2006, 312:2515-2527.
35. Obermajer N., Doljak B., Jamnik P., Fonovic U.P., Kos J. Cathepsin X cleaves the C-terminal dipeptide of alpha- and gamma-enolase and impairs survival and neuritogenesis of neuronal cells. Int J Biochem Cell Biol 2009, 41:1685-1696.
36. Staudt N.D., Aicher W.K., Kalbacher H., Stevanovic S., Carmona A.K., Bogyo M., et al. Cathepsin X is secreted by human osteoblasts, digests CXCL-12 and impairs adhesion of hematopoietic stem and progenitor cells to osteoblasts. Haematologica 2010, 95:1452-1460.
37. Nagler D.K., Kraus S., Feierler J., Mentele R., Lottspeich F., Jochum M., et al. A cysteine-type carboxypeptidase, cathepsin X, generates peptide receptor agonists. Int Immunopharmacol 2010, 10:134-139.
38. Ratovitski T., Chighladze E., Waldron E., Hirschhorn R.R., Ross C.A. Cysteine proteases bleomycin hydrolase and cathepsin Z mediate N-terminal proteolysis and toxicity of mutant huntingtin. J Biol Chem 2011, 286:12578-12589.
39. Pecar Fonovic U., Jevnikar Z., Rojnik M., Doljak B., Fonovic M., Jamnik P., et al. Profilin 1 as a target for cathepsin X activity in tumor cells. PLOS ONE 2013, 8:e53918.
40. Santamaria I., Velasco G., Pendas A.M., Fueyo A., Lopez-Otin C. Cathepsin Z, a novel human cysteine proteinase with a short propeptide domain and a unique chromosomal location. J Biol Chem 1998, 273:16816-16823.
41. Nagler D.K., Menard R. Human cathepsin X: a novel cysteine protease of the papain family with a very short proregion and unique insertions. FEBS Lett 1998, 434:135-139.
42. Nascimento F.D., Rizzi C.C.A., Nantes I.L., Stefe L., Turk B., Carmona A.K., et al. Cathepsin X binds to cell surface heparan sulfate proteoglycans. Arch Biochem Biophys 2005, 436:323-332.
43. Lechner A.M., Assfalg-Machleidt I., Zahler S., Stoeckelhuber M., Machleidt W., Jochum M., et al. RGD-dependent binding of procathepsin X to integrin alphavbeta3 mediates cell-adhesive properties. J Biol Chem 2006, 281:39588-39597.
44. Lines K.E., Chelala C., Dmitrovic B., Wijesuriya N., Kocher H.M., Marshall J.F., et al. S100P-binding protein, S100PBP, mediates adhesion through regulation of cathepsin Z in pancreatic cancer cells. Am J Pathol 2012, 180:1485-1494.
45. Jevnikar Z., Obermajer N., Pecar-Fonovic U., Karaoglanovic-Carmona A., Kos J. Cathepsin X cleaves the beta2 cytoplasmic tail of LFA-1 inducing the intermediate affinity form of LFA-1 and alpha-actinin-1 binding. Eur J Immunol 2009, 39:3217-3227.
46. Burns S., Hardy S.J., Buddle J., Yong K.L., Jones G.E., Thrasher A.J. Maturation of DC is associated with changes in motile characteristics and adherence. Cell Motil Cytoskeleton 2004, 57:118-132.
47. Obermajer N., Svajger U., Bogyo M., Jeras M., Kos J. Maturation of dendritic cells depends on proteolytic cleavage by cathepsin X. J Leukoc Biol 2008, 84:1306-1315.
48. Porter J.C., Bracke M., Smith A., Davies D., Hogg N. Signaling through integrin LFA-1 leads to filamentous actin polymerization and remodeling, resulting in enhanced T cell adhesion. J Immunol 2002, 168:6330-6335.
49. Jevnikar Z., Obermajer N., Kos J. LFA-1 fine-tuning by cathepsin X. IUBMB Life 2011, 63:686-693.
50. Obermajer N., Jevnikar Z., Doljak B., Sadaghiani A.M., Bogyo M., Kos J. Cathepsin X-mediated beta2 integrin activation results in nanotube outgrowth. Cell Mol Life Sci 2009, 66:1126-1134.
51. Walter L., Neumann H. Role of microglia in neuronal degeneration and regeneration. Semin Immunopathol 2009, 31:513-525.
52. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69.
53. Wendt W., Schulten R., Stichel C.C., Lubbert H. Intra- versus extracellular effects of microglia-derived cysteine proteases in a conditioned medium transfer model. J Neurochem 2009, 110:1931-1941.
54. Hattori T., Takei N., Mizuno Y., Kato K., Kohsaka S. Neurotrophic and neuroprotective effects of neuron-specific enolase on cultured neurons from embryonic rat brain. Neurosci Res 1995, 21:191-198.
55. Hafner A., Obermajer N., Kos J. gamma-1-syntrophin mediates trafficking of gamma-enolase towards the plasma membrane and enhances its neurotrophic activity. Neurosignals 2010, 18:246-258.
56. Hafner A., Obermajer N., Kos J. gamma-Enolase C-terminal peptide promotes cell survival and neurite outgrowth by activation of the PI3K/Akt and MAPK/ERK signalling pathways. Biochem J 2012, 443:439-450.
57. Hafner A., Glavan G., Obermajer N., Zivin M., Schliebs R., Kos J. Neuroprotective role of gamma-enolase in microglia in a mouse model of Alzheimer's disease is regulated by cathepsin X. Aging Cell 2013, 12:604-614.
58. Tapia F.J., Polak J.M., Barbosa A.J., Bloom S.R., Marangos P.J., Dermody C., et al. Neuron-specific enolase is produced by neuroendocrine tumours. Lancet 1981, 1:808-811.
59. Jang S.M., Kim J.W., Kim C.H., Kim D., Rhee S., Choi K.H. p19(ras) represses proliferation of non-small cell lung cancer possibly through interaction with Neuron-Specific Enolase (NSE). Cancer Lett 2010, 289:91-98.
60. Masoudi-Nejad A., Asgari Y. Metabolic cancer biology: structural-based analysis of cancer as a metabolic disease, new sights and opportunities for disease treatment. Semin Cancer Biol 2014.
61. Dang C.V., Semenza G.L. Oncogenic alterations of metabolism. Trends Biochem Sci 1999, 24:68-72.
62. Yan T., Skaftnesmo K.O., Leiss L., Sleire L., Wang J., Li X., et al. Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide. BMC Cancer 2011, 11:524.
63. Bhutani N., Piccirillo R., Hourez R., Venkatraman P., Goldberg A.L. Cathepsins L and Z are critical in degrading polyglutamine-containing proteins within lysosomes. J Biol Chem 2012, 287:17471-17482.
64. Hidaka S., Yasutake T., Takeshita H., Kondo M., Tsuji T., Nanashima A., et al. Differences in 20q13.2 copy number between colorectal cancers with and without liver metastasis. Clin Cancer Res 2000, 6:2712-2717.
65. Buhling F., Peitz U., Kruger S., Kuster D., Vieth M., Gebert I., et al. Cathepsins K, L, B, X and W are differentially expressed in normal and chronically inflamed gastric mucosa. Biol Chem 2004, 385:439-445.
66. Decock J., Obermajer N., Vozelj S., Hendrickx W., Paridaens R., Kos J. Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer. Int J Biol Markers 2008, 23:161-168.
67. Kolwijck E., Kos J., Obermajer N., Span P.N., Thomas C.M., Massuger L.F., et al. The balance between extracellular cathepsins and cystatin C is of importance for ovarian cancer. Eur J Clin Invest 2010, 40:591-599.
68. Zhang X., Hou Y., Niu Z., Li W., Meng X., Zhang N., et al. Clinical significance of detection of cathepsin X and cystatin C in the sera of patients with lung cancer. Zhongguo Fei Ai Za Zhi 2013, 16:411-416.
69. Vizin T., Christensen I.J., Wilhelmsen M., Nielsen H.J., Kos J. Prognostic and predictive value of cathepsin X in serum from colorectal cancer patients. BMC Cancer 2014, 14:259.
70. Vasiljeva O., Papazoglou A., Kruger A., Brodoefel H., Korovin M., Deussing J., et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res 2006, 66:5242-5250.
71. Sevenich L., Schurigt U., Sachse K., Gajda M., Werner F., Muller S., et al. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci U S A 2010, 107:2497-2502.
72. Buhler A., Berger S., Bengsch F., Martin G., Han H., Vierkotten S., et al. Cathepsin proteases promote angiogenic sprouting and laser-induced choroidal neovascularisation in mice. Exp Eye Res 2013, 115:73-78.
73. Janke J., Schluter K., Jandrig B., Theile M., Kolble K., Arnold W., et al. Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1. J Exp Med 2000, 191:1675-1686.
74. Braun M., Fountoulakis M., Papadopoulou A., Vougas K., Seidel I., Holler T., et al. Down-regulation of microfilamental network-associated proteins in leukocytes of breast cancer patients: potential application to predictive diagnosis. Cancer Genomics Proteomics 2009, 6:31-40.
75. Wu N., Zhang W., Yang Y., Liang Y.L., Wang L.Y., Jin J.W., et al. Profilin 1 obtained by proteomic analysis in all-trans retinoic acid-treated hepatocarcinoma cell lines is involved in inhibition of cell proliferation and migration. Proteomics 2006, 6:6095-6106.
76. Zoidakis J., Makridakis M., Zerefos P.G., Bitsika V., Esteban S., Frantzi M., et al. Profilin 1 is a potential biomarker for bladder cancer aggressiveness. Mol Cell Proteomics 2012, 11. M111.009449.
77. Gronborg M., Kristiansen T.Z., Iwahori A., Chang R., Reddy R., Sato N., et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 2006, 5:157-171.
78. Skvortsov S., Jimenez C.R., Knol J.C., Eichberger P., Schiestl B., Debbage P., et al. Radioresistant head and neck squamous cell carcinoma cells: intracellular signaling, putative biomarkers for tumor recurrences and possible therapeutic targets. Radiother Oncol 2011, 101:177-182.
79. Skvortsova I. Profilin 1: do we have a novel proteome-found biomarker predicting response to anticancer therapy?. Proteomics 2013, 13:2069-2071.
80. Roy P., Jacobson K. Overexpression of profilin reduces the migration of invasive breast cancer cells. Cell Motil Cytoskeleton 2004, 57:84-95.
81. Witke W. The role of profilin complexes in cell motility and other cellular processes. Trends Cell Biol 2004, 14:461-469.
82. Ding Z., Bae Y.H., Roy P. Molecular insights on context-specific role of profilin-1 in cell migration. Cell Adh Migr 2012, 6:442-449.
83. Jockusch B.M., Murk K., Rothkegel M. The profile of profilins. Rev Physiol Biochem Pharmacol 2007, 159:131-149.
84. Kraus S., Bunsen T., Schuster S., Cichon M.A., Tacke M., Reinheckel T., et al. Cellular senescence induced by cathepsin X downregulation. Eur J Cell Biol 2011, 90:678-686.
85. Kraus S., Fruth M., Bunsen T., Nagler D.K. IGF-I receptor phosphorylation is impaired in cathepsin X-deficient prostate cancer cells. Biol Chem 2012, 393:1457-1462.
86. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119:1420-1428.
87. Sadaghiani A.M., Verhelst S.H., Gocheva V., Hill K., Majerova E., Stinson S., et al. Design, synthesis, and evaluation of in vivo potency and selectivity of epoxysuccinyl-based inhibitors of papain-family cysteine proteases. Chem Biol 2007, 14:499-511.